ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Boehringer Ingelheim boosts KRas cancer program

by Ryan Cross
September 6, 2019 | APPEARED IN VOLUME 97, ISSUE 35

 

Boehringer Ingelheim is teaming up with the Mumbai, India–based drug company Lupin to bolster its KRas inhibitor program for gastrointestinal and lung cancers. Lupin has developed an inhibitor of MEK, a protein downstream of KRas. Boehringer will pay Lupin $20 million up front to license and test Lupin’s MEK inhibitor in combination with a KRas inhibitor. Lupin could also receive more than $700 million in future milestone payments. Separately, Boehringer recently announced a drug development partnership with the University of Texas MD Anderson Cancer Center to test its KRas inhibitors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment